Post-Surgery Recovery
88
シナジー
3
7,000
intermediate
May 17, 2026
概要
The Post-Surgery Recovery stack is designed for accelerated healing following surgical procedures, combining tissue-repair peptides with immune support to address the dual challenges of wound healing and infection prevention. BPC-157 at standard dosing promotes angiogenesis and growth factor expression at surgical sites, while TB-500 is used at a higher loading dose (5000mcg) to maximize its systemic anti-inflammatory and tissue-migration effects during the critical early post-operative window. Thymosin Alpha-1 (Ta1) is the immune-support cornerstone of this stack. It is a 28-amino-acid peptide originally isolated from thymic tissue that enhances T-cell maturation, dendritic cell activation, and natural killer cell function. Ta1 is approved in over 35 countries under the brand name Zadaxin for hepatitis B/C and as an immune adjuvant. In the post-surgical context, it helps prevent opportunistic infections during the immunosuppressive period following anesthesia and surgical trauma, while also modulating inflammation to prevent excessive scarring. The synergy here is particularly elegant: BPC-157 and TB-500 handle the structural repair — new blood vessel formation, cellular migration, extracellular matrix deposition, and anti-inflammatory signaling — while Thymosin Alpha-1 ensures the immune system remains vigilant against post-surgical infections without triggering excessive inflammatory responses that could impair healing. This combination addresses the clinical reality that surgical recovery requires both tissue repair and immune competence, and that these processes must be balanced rather than maximized independently. This stack should only be used under physician supervision, ideally beginning 24-48 hours after surgery once initial hemostasis is established.
投与プロトコル
250 mcg
1回の投与あたり
5,000 mcg
1回の投与あたり
1,500 mcg
1回の投与あたり
目標と証拠
警告
- Must be supervised by prescribing physician. BPC-157 and TB-500 were removed from FDA Category 2 (April 2026) but remain pending PCAC review — not legal to compound yet. Thymosin Alpha-1 remains FDA Category 2 (restricted) in the US (approved abroad in 35+ countries as Zadaxin).
Comments
Sign in to join the discussion
注意: このスタックはコミュニティから提出され、研究用のみです。Peptide Contactsは提出されたスタックの安全性や効果性を確認していません。使用するペプチドプロトコル前に常に資格のある医療専門家に相談してください。